治疗前人乳头瘤病毒DNA状态对宫颈癌的预后价值
本研究纳入248例宫颈癌患者,术前或同步放化疗前检测HPV DNA。多因素分析显示HPV阴性者无病生存期(DFS)较HPV阳性者差(HR 3.97,95%CI 1.84-8.58,p=0.0005),HPV 16阳性者DFS较好(HR 0.41,95%CI 0.23-0.72,p=0.0019)。作者认为治疗前HPV DNA状态可能是有用的预后生物标志物,但需更大样本和更全面研究验证。
要点
- HPV阴性宫颈癌患者DFS显著差于HPV阳性者(HR 3.97,95%CI 1.84-8.58,p=0.0005)。
- HPV 16阳性者DFS显著优于HPV 16阴性者(HR 0.41,95%CI 0.23-0.72,p=0.0019)。
- 手术组仅HPV 16阳性与DFS显著相关;CCRT组仅HPV阴性显著相关。
核心结论
- 治疗前HPV DNA状态可能是有用的宫颈癌预后生物标志物;HPV 16 DNA存在与较好DFS相关,HPV阴性则与较差DFS相关,但需更大样本和更全面研究验证。
研究设计与样本
- 纳入248例在手术或同步放化疗(CCRT)前提供宫颈细胞标本进行HPV基因分型的合格患者。
- 其中108例因FIGO IB1-IIA期宫颈癌接受根治性子宫切除术,140例因FIGO IB2-IV期宫颈癌接受CCRT。
主要发现
- HPV 16和18是最常见的两种HPV类型,检出率分别为52.4%和12.5%。
- 治疗前HPV DNA检测显示18.5%的宫颈癌为HPV阴性。
- 多因素分析显示HPV阴性者DFS较HPV阳性者差(HR 3.97,95%CI 1.84-8.58,p=0.0005)。
- HPV 16阳性宫颈癌患者DFS较好(HR 0.41,95%CI 0.23-0.72,p=0.0019)。
- 手术组中仅HPV 16阳性与DFS显著相关(HR 0.34,95%CI 0.12-0.96,p=0.0416);CCRT组中仅HPV阴性显著相关(HR 3.75,95%CI 1.78-7.90,p=0.0005)。
临床怎么用
- 原文未据此给出推荐;作者认为治疗前HPV DNA状态可能是有用的预后生物标志物,但需更大样本和更全面研究验证。
局限性
- 原文指出需要更大样本量和更全面的研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although the relationship between human papilloma virus (HPV) and cervical cancer is well established, the prognostic value of HPV status has not been determined, largely because previous studies have yielded conflicting results. This study aimed to investigate the prognostic value of pre-treatment HPV DNA for predicting tumor recurrence in cervical cancer. METHODS: The study included 248 eligible patients who provided cervical cell specimens for HPV genotyping before surgery or concurrent chemoradiotherapy (CCRT). Of these 248 patients, 108 were treated with radical hysterectomy for International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer, and 140 were treated with CCRT for FIGO stage IB2-IV cervical cancer. RESULTS: HPV 16 and 18 were the two most common HPV types detected, with prevalence rates of 52.4% and 12.5%, respectively. The pre-treatment HPV DNA test showed that 18.5% of cervical cancers were HPV negative. Multivariate analysis showed that HPV negativity was associated with poorer disease-free survival (DFS) than HPV-positive status (hazard ratio [HR], 3.97; 95% confidence interval [CI], 1.84-8.58; p=0.0005), and patients with HPV 16-positive cancers had better DFS (HR, 0.41; 95% CI, 0.23-0.72; p=0.0019). In the surgery group, only HPV 16 positivity was significantly correlated with DFS (HR, 0.34; 95% CI, 0.12-0.96; p=0.0416). In the CCRT group, only HPV negativity was significantly correlated with DFS (HR, 3.75; 95% CI, 1.78-7.90; p=0.0005). CONCLUSIONS: Pre-treatment HPV DNA status may be a useful prognostic biomarker in cervical cancer. The presence of HPV 16 DNA was associated with better DFS, and HPV negativity was associated with worse DFS. However, larger sample sizes and more comprehensive studies are required to verify our findings.
引用
- Chong GO, Lee YH, Han HS, et al. Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer. Gynecol Oncol. 2017. PMID: 29153540. doi:10.1016/j.ygyno.2017.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。